Heather Hain
Corporate Officer/Principal chez Society For Neuroscience
Profil
Heather Hain is currently a Member at the Society for Neuroscience.
Previously, she worked as a Director-Scientific Operations at Melior Discovery, Inc. and as a Senior Scientist at Xenogen Corp.
She was also a Member at The Pfizer Foundation, Inc. from 1999 to 2001.
Dr. Hain earned a doctorate degree from Oregon Health & Science University in 1999.
Postes actifs de Heather Hain
| Sociétés | Poste | Début |
|---|---|---|
Society For Neuroscience
 Society For Neuroscience Miscellaneous Commercial ServicesCommercial Services The Society for Neuroscience is an organization with over 36,000 members in more than 95 countries. The non-profit company is based in Washington. The organization also engages in science advocacy and public policy, including an annual Capitol Hill Day, and has various public outreach efforts, such as the interactive collection of public-facing resources on BrainFacts.org. It was founded in 1969 and offers year-round programming, including the publication of two scientific journals, professional development resources, and career training through Neuronline. | Corporate Officer/Principal | - |
Anciens postes connus de Heather Hain
| Sociétés | Poste | Fin |
|---|---|---|
Melior Discovery, Inc.
 Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Directeur des opérations | 21/10/2009 |
The Pfizer Foundation, Inc.
 The Pfizer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., The Pfizer Foundation, Inc. is a company committed to transparency and disclosure of activities of public interest. The company is based in New York, NY. Pfizer is dedicated to discovering breakthrough treatments, including medicines and vaccines, to benefit patients worldwide. The company is focused on treating 225 million people with these breakthrough treatments by 2025. The company's areas of interest include funding for educational activities, health education, and scientific research. Additionally, Pfizer is exploring the potential of mRNA technology to fight viruses and is working to understand the differences between biologics and biosimilars, particularly in terms of cost. | Corporate Officer/Principal | 01/01/2001 |
Xenogen Corp.
 Xenogen Corp. Medical SpecialtiesHealth Technology Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA. | Corporate Officer/Principal | - |
Formation de Heather Hain
| Oregon Health & Science University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Melior Discovery, Inc.
Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Commercial Services |
Society For Neuroscience
Society For Neuroscience Miscellaneous Commercial ServicesCommercial Services The Society for Neuroscience is an organization with over 36,000 members in more than 95 countries. The non-profit company is based in Washington. The organization also engages in science advocacy and public policy, including an annual Capitol Hill Day, and has various public outreach efforts, such as the interactive collection of public-facing resources on BrainFacts.org. It was founded in 1969 and offers year-round programming, including the publication of two scientific journals, professional development resources, and career training through Neuronline. | Commercial Services |
Xenogen Corp.
Xenogen Corp. Medical SpecialtiesHealth Technology Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA. | Health Technology |
The Pfizer Foundation, Inc.
The Pfizer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., The Pfizer Foundation, Inc. is a company committed to transparency and disclosure of activities of public interest. The company is based in New York, NY. Pfizer is dedicated to discovering breakthrough treatments, including medicines and vaccines, to benefit patients worldwide. The company is focused on treating 225 million people with these breakthrough treatments by 2025. The company's areas of interest include funding for educational activities, health education, and scientific research. Additionally, Pfizer is exploring the potential of mRNA technology to fight viruses and is working to understand the differences between biologics and biosimilars, particularly in terms of cost. | Commercial Services |
